GLP-1 receptor agonists and SGLT2 inhibitors, although not currently approved for MASLD treatment in T1D, have shown benefits in reducing hepatic steatosis and improving metabolic parameters in T2D and may offer future therapeutic options [33]. Here, SLC5A2 is linked to fatty liver disease.